A therosclerosis, the primary cause of ischemic cardiomyopathy and ultimately a major contributing factor to death in the Western world today, obviously is a very significant burden on society and as such is the focus of a considerable amount of research. Urotensin II (UII) is emerging as a prominent vasoactive factor in a variety of cardiovascular diseases including atherosclerosis through its interaction with its receptor, UT. This was first suggested by Ames et al, who described UII immunoreactivity in human coronary atheroma. 1 Indeed, UII and its receptor are widely expressed in various tissues and organs in human and animals. 1, 2 Pharmacological studies have demonstrated a varying degree of vasoactive properties for UII, the extent of which depends on the anatomic location and species studied. [1] [2] [3] In addition, both Sauzeau et al as well as Watanabe et al demonstrated that UII induced smooth muscle cell (SMC) proliferation, an integral step in the early development of atherosclerotic plaques. 4, 5 Interestingly, Watanabe et al demonstrated a synergistic effect of UII on proliferation of SMCs when administered with oxidized low-density lipoprotein (LDL) through activation of ␣ q /␣ 11 G-protein subunit and generation of reactive oxygen species (ROS). 5 UII has also been shown to increase expression of NADPH oxidase and plasminogen activator inhibitor-1 (PAI-1) in vascular SMCs. 6 UII was found to be elevated in human atherosclerotic arteries. In fact, we were the first to show increased mRNA and protein levels of UII in atherosclerotic human aortae. 7 Furthermore, we demonstrated that UT mRNA levels were also increased in diseased human aortae. Later on, we demonstrated that UII protein and mRNA levels were significantly increased in arteries of patients with coronary atherosclerosis compared to normal coronary arteries. 8 These findings suggest a potential role for UII in the pathogenesis of coronary atherosclerosis.
Our findings are supported by Maguire et al who found prominent UII immunoreactivity in atherosclerotic plaques of coronary arteries as well as in the thickened intima of failed saphenous vein grafts of explanted human hearts. 9 In addition to increased UII levels in atherosclerotic lesions, reports have demonstrated increased UII levels in plasma of patients with atherosclerotic disease. 10, 11 On the other hand, UT mRNA was shown to be significantly upregulated and UII radioligand binding was significantly elevated in the aortae of apolipoprotein E (ApoE) knockout (KO) mice, an established model for the study of atherosclerosis. 12 Furthermore, recent studies have shown that UII induced foam cell formation through increased acetyl-LDL-induced cholesterol ester accumulation without affecting scavenger receptor A activity; and it increases monocyte chemotaxis. 1314 UT is expressed in monocytes, and its mRNA and protein expression is induced by inflammatory cytokines through stimulation of NF-B. 7, 14 Thus, both UII and UT are upregulated in atherosclerotic arteries of humans and in aortae of ApoE KO mice. Also UII induces SMC proliferation alone and in a synergistic fashion with oxidized LDL, a major contributor to atherosclerosis. These data support a role for UII as a contributing factor in the pathophysiology of atherosclerosis. To determine the pathological significance of UII in the etiology of experimental atherosclerosis, we examined the effect of UT deletion in ApoE KO mice fed a high-fat Western diet.
Methods

Study Design
We previously generated UTKO mice as described in the online supplement. Mice were bred and allowed to mature to 6 weeks of age, at which point male mice were weighed and put on a high-fat diet for a period of 12 weeks. The high-fat diet (TD-88137, Harlan Teklad) consisted of 42% calories from fat with 0.15% cholesterol content. 15 At the conclusion of the study period, mice were fasted for 4 hours, weighed, and then euthanized by exsanguination under anesthesia. We then collected serum and organs such as heart, aorta, lungs, liver, kidneys, and spleen. Each organ was weighed and then fixed in 10% formalin or flash frozen in liquid nitrogen and stored at Ϫ80°C.
Details regarding strain development, tissue histology, serum lipids, serum insulin, serum glucose, real-time RT-PCR, Western blotting, immunofluorescence, lipid uptake, acyl-CoA:cholesterol acyltransferase (ACAT) activity assay, and statistics are in the supplemental data (available online at http://circres.ahajournals.org).
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Hemodynamics
In light of the vasoactive properties of UII and the fact that hypertension is a prominent risk factor in the development of atherosclerosis, 16 we assessed hemodynamic profiles of UTKO mice. The latter exhibited significantly elevated systolic blood pressure and pulse pressure compared to wild-type (WT) mice (Figure 1 ).
Gross Anatomy
We measured body weight at the beginning and end of the 12-week study period. Interestingly, we found that UT KO mice had a significant reduction in body weight gain compared to WT mice (PϽ0.001; Online Table I ). Of note, double knockout (DKO) mice experienced the least weight gain of all the strains. Specifically, DKO mice had significantly lesser weight gain compared to WT mice and ApoE KO mice (PϽ0.05), but not compared to UT KO mice.
We also measured organ weights at time of sacrifice including heart, right and left lungs, liver, right and left kidneys, and spleen. Interestingly, UT KO mice exhibited significantly reduced liver mass compared to WT mice (PϽ0.01; Online Table I ), however all other organs had comparable weights. Similar to UT KO mice, DKO mice also had decreased liver weights, which was significant when compared to both WT and ApoE KO mice (PϽ0.05). Of note, DKO mice had significantly increased heart, lungs, kidneys, and spleen weights compared to all other strains (PϽ0.05). This latter data are especially remarkable in light of the fact that DKO mice had the least body weight gain.
Lesion Area Fraction
WT C57BL/6 mice demonstrated negligible atherosclerosis after exposure to a high-fat diet for 12 weeks (Figure 2A-D Figure 2E ). Of note, 2 of 11 aortae from the DKO mice developed abdominal aortic aneurysms, a phenomenon that was not observed in any other strains (Online Figure II) . The first of these 2 cases exhibited such extensive atherosclerosis that Ͼ85% of the aorta was diseased. The latter 2 aortas were not included in the lesion area analysis because of their extreme deviation from the mean.
Lesion Histology
As expected from the en face aortic analysis, lesions were absent from WT and UT KO aortic root ( Figure 2F , 2G, 2J, and 2K). On the other hand, ApoE KO and DKO animals both presented with lesions or varying sizes. Atherosclerotic plaques varied from Type 1 lesions exhibiting intimal thickening to type V lesions bearing large fatty cores with overlying fibrous caps ( Figure 2H , 2I, 2L, and 2M). All lesions had pronounced inflammatory infiltrates. No major histological differences in lesions were noted between ApoE KO and DKO animals as evident by Mac 2, ␣-SMC actin, and elastin staining (Online Figure III) , however the largest lesions were found in DKO animals.
Serum Glucose, Insulin and Lipids
Serum glucose was similar for all strains; however, DKO mice exhibited a marked increase in serum insulin levels (PϽ0.001, Figure 3A ). UT KO mice had serum total cholesterol levels comparable to WT mice. As expected, ApoE KO mice demonstrated a very significant increase in serum total cholesterol compared to WT and UT KO animals (PϽ0.001; Figure 3B ), which is in accordance with levels reported by others. 17 Remarkably, DKO had even greater serum total cholesterol levels, which were significantly increased compared to all other strains including ApoE KO mice (Pϭ0.001). Serum triglyceride analysis revealed that UT KO mice exhibited a small increase in serum triglycerides compared to WT mice ( Figure 3B ). ApoE KO mice showed a significant increase in serum triglycerides compared to WT and UT KO mice (PϽ0.001). DKO mice demonstrated triglyceride levels greater than all other strains including ApoE KO (Pϭ0.001; Figure 3B ).
Fractioning of serum lipoprotein by HPLC showed increased content of cholesterol in the very low-density lipoprotein (VLDL)-sized fraction in ApoE KO compared to WT and UT KO, and was greatest in DKO mice ( Figure 3C ). Cholesterol content of LDL was higher in UT KO, ApoE KO, and DKO compared to WT mice. Cholesterol content of high-density lipoprotein (HDL) was lower in ApoE KO and DKO mice compared to UTKO and WT mice. Interestingly, cholesterol content was elevated in both the LDL and HDL fractions in UT KO mice compared to WT mice.
Triglyceride content of the VLDL-sized fraction was higher in ApoE KO mice compared to WT or UT KO mice, and again it was highest in DKO mice ( Figure 3D ). In addition, DKO also had higher free triglycerides than both ApoEKO and WT mice, however the highest levels were seen in UTKO mice ( Figure 3D ). It is worth mentioning that the hyperlipidemic and atherosclerotic phenotype seen in DKO mice is seen in male and female mice only when fed a high-fat diet (data not shown).
Liver Histology
The significant reduction in liver size in both UT KO and DKO mice led us to analyze liver histology. Analysis of H&E-stained livers demonstrated that WT had apparent hepatic steatosis ( Figure 4A ). Of note, the hepatic steatosis was significantly decreased in UTKO mice compared to WT mice (PϽ0.05) ( Figure 4B and 4E) . Similarly, DKO mice had markedly reduced hepatic steatosis which was significant when compared to all other strains (PϽ0.01; Figure 4D and 4E).
Lipid Uptake
To assess whether the observed reduction in hepatic steatosis was related to decreased lipid uptake we performed a lipoprotein binding and uptake assay of LDL and ␤VLDL remnants in cultured mouse primary hepatocytes from WT, ApoE KO, and UTKO mice. Interestingly, there was a marked and significant reduction in LDL binding (data not shown) and uptake in UTKO mouse hepatocytes compared to both WT and ApoE KO mice ( Figure 5 ). In ApoE KO hepatocytes, we found a significant decrease in ␤VLDL binding and a small but not significant reduction in ␤VLDL uptake compared to WT cells (data not shown), supporting a role of ApoE in the uptake of ␤VLDL. The decreased LDL uptake in UTKO mice supports the hypothesis of reduced lipid uptake in DKO mice generating reduced hepatic steatosis ( Figure 4 ) and increased hyperlipidemia (Figure 3) .
Expression of Liver Lipid Transporters and Nuclear Receptors
The marked reduction in hepatic steatosis in DKO mice and the reduction in lipid uptake in UTKO hepatocytes suggested that UT deficiency may be associated with a reduction in lipid transporters or uptake receptors. Therefore, we analyzed mRNA levels from liver tissue of the 4 strains of mice.
Specifically, we analyzed the mRNA levels of the LDL receptor (LDLR), the LDLR-related protein (LRP), the ATP binding cassette-A1 (ABCA1), ATP binding cassette-G5 (ABCG5), scavenger receptor-A1 (SR-A1), and SR-B1. The mRNA expression for these transporters and receptors were reduced in UTKO mice compared to WT mice but this reduction did not reach statistical significance. In contrast, LRP, ABCA1, SR-A1, and SR-B1 were all significantly elevated in ApoE KO mice (PϽ0.05) compared to WT and UT KO (Online Table III ). Of note, the mRNA levels for ABCA1, SR-A1, and SR-B1 were significantly reduced in DKO mice compared to ApoE KO mice (PϽ0.05) ( Figure 6A through 6C and Online Table III ). Protein levels of SR-A1 were also significantly reduced in UT KO and DKO mice compared to WT and ApoE KO, respectively (PϽ0.05; Figure 7A ). Interestingly, LRP levels remained significantly elevated in DKO mice compared to WT and UT KO mice (Online Table III ). The mRNAs for LDL receptor and ABCG5 did not differ significantly among the different experimental groups.
These lipid transporters and uptake receptors are transcriptionally regulated by a group of nuclear receptors including liver X receptor-␣ (LXR-␣), as well as the peroxisome proliferator activated receptors (PPARs) ␣, ␦, and ␥. Therefore, mRNA analysis of the latter receptors was evaluated. The results indicated that mRNAs for all the nuclear receptors were reduced in UT KO mice compared to WT mice, but this reduction did not reach statistical significance. In contrast, both LXR-␣ and PPAR-␦ mRNA expression levels were significantly increased in ApoE KO mice compared to WT and UT KO mice (PϽ0.01). Importantly, there was a significant reduction in the expression of LXR-␣, PPAR-␦, and ␥ in DKO mice compared to ApoE KO mice (Figure 6D through 6F; PϽ0.01). Western blot analysis showed that although expression of LXR-␣ protein was not significantly different between WT and UT KO, it was significantly elevated in ApoE KO mice. In contrast, DKO mice had a significantly reduced levels of LXR-␣ protein compared to ApoE KO mice (PϽ0.05; Figure 7B ). There was no significant difference in the protein levels of other receptors and nuclear proteins between ApoE KO and DKO mice.
UII Upregulates ACAT Expression and Activity
Because UII has been previously shown to induce the expression of ACAT in macrophages, 13 we sought to determine whether the reverse occurred in our mouse model of UT gene deletion. Indeed, we found that ACAT protein expression was significantly reduced in DKO mice compared to their ApoE KO littermates ( Figure 7C ). Furthermore, we determined whether UII had any effects on ACAT activity in hepatocytes. To this end, we performed a cholesterol esterification assay in primary mouse hepatocytes in which the basal level of intracellular cholesterol esterification was compared to cells treated either with an ACAT inhibitor, UII alone, UII ϩ ACAT inhibitor, UII ϩ a mitogen activated protein kinase and extra-cellular-signal regulated kinase kinase (MEK) inhibitor (PD98059), UII ϩ a p38 kinase inhibitor (SB203580), or UII ϩ ACAT inhibitor ϩ PD98059 (Figure 8 ). Interestingly, we found that UII significantly increased ACAT activity evident by significantly elevated cholesterol esterification in mouse primary hepatocytes. UIIinduced ACAT activity was abolished by the addition of the MEK inhibitor PD98059, but not by the p38 kinase inhibitor, SB203580. Furthermore, the addition of both the MEK inhibitor and the ACAT inhibitor simultaneously in the presence of UII did not further reduce cholesterol esterification than by addition of the UII and ACAT inhibitor. These results suggest that cholesteryl ester formation is inducible with UII administration in hepatocytes as in macrophages, and this activation is dependent on ACAT and MEK. Furthermore, immunohistochemical analysis showed that ACAT protein expression was reduced specifically in the DKO hepatocytes ( Figure 7D through 7G) , suggesting impaired UII-induced ACAT expression.
Discussion
Here we show that UT gene deletion leads to (1) elevated systolic and pulse pressure, (2) decreased LDL uptake in the liver, (3) hypertriglyceridemia, (4) reduced hepatic steatosis, and (5) reduced liver mass. In addition, UT gene deletion combined with ApoE gene deletion also leads to: (1) hyperlipidemia, (2) hyperinsulinemia, and (3) exaggerated atherosclerotic lesion formation in the aorta.
The elevated serum lipids in DKO animals is likely to be the main contributor to the significant increase in atherosclerotic burden compared to ApoE KO mice. However, the elevated systolic pressure and hyperinsulinemia, two wellestablished risk factors of atherosclerosis, may also potentially contribute to the enhanced atherosclerotic state in DKO animals. Indeed together, the hyperlipidemia, hyperinsulinemia, and hypertension provide strong mechanistic evidence for the observed atherosclerosis in DKO mice.
UII has been shown as a potent vasoconstrictor of main blood vessels, conversely there was a strong evidence for vasodilatory role for UII in peripheral vessels. 1,18 -20 These findings are further supported by the report that UII deletion in mice is associated with increased systolic pressure. 21 Furthermore, the striking hyperinsulinemia in a euglycemic context in DKO mice suggests that these mice have insulin resistance. The hyperinsulinemia may be a consequence of the exaggerated hyperlipidemia in DKO mice; however, it may also be a direct result of UT deficiency. Indeed, UII has previously been shown to inhibit insulin secretion in the perfused rat pancreas. 22 The liver is an integral organ in the regulation of lipid metabolism. UII and UT are both expressed in the liver, and recent data have suggested an important role for UII in chronic liver disease and metabolic syndromes. 1, [23] [24] [25] Therefore, it was of great interest to find that UT gene deletion led to significantly reduced liver mass and hepatic steatosis, regard- less of strain background. The decreased steatosis is likely attributable to either a reduction in liver uptake and storage of lipids, increased lipid export, or an increase in lipid oxidation.
To determine whether the decreased steatosis and associated hyperlipidemia was in fact a result of reduced lipid uptake, we performed a lipoprotein uptake assay using hepatocytes isolated from WT, ApoE KO, and UTKO mice. We found that UTKO exhibited a significant reduction in LDL binding and uptake compared to both WT and ApoE KO mice, supporting the hypothesis that the reduced hepatic steatosis in UTKO and DKO mice is the result of reduced lipid uptake.
The reduced lipid uptake suggests that there would be a reduction in the abundance or activity of lipoprotein uptake receptors. Therefore, we analyzed the mRNA and protein expression of lipid transporters including the LDL receptor, LRP, ABCA1, SR-A1, and SR-B1 in the livers from all 4 strains. Interestingly, we found significant reductions in the mRNA levels of ABCA1, SR-A1, and SR-B1 in DKO mice. The protein expression of SR-A1 was also significantly decreased in DKO mice. Therefore, the reduction in lipoprotein uptake in the liver of DKO animals may be a consequence of the reduction in this latter receptor. This is in accordance with several studies which show that scavenger receptor deficiency increases plasma cholesterol and aggravates atherosclerosis in hyperlipidemic mice. 26 -29 Furthermore, overexpression of SR-B1 led to a significant decrease in plasma HDL and non-HDL cholesterol levels. 30 Therefore, these latter studies support the notion that the reduction in scavenger receptor as observed in DKO mice can lead to serum hyperlipidemia.
To investigate whether the effect of UT deficiency plays a role upstream of the lipid transport and uptake receptors we analyzed the expression of nuclear receptors known to regulate the transcriptional expression of the former. Of note, we found that the mRNA levels for LXR-␣, PPAR-␦, and PPAR-␥ were all significantly decreased in DKO mice compared to ApoE KO mice. Furthermore, we went on to demonstrate that LXR-␣ was also significantly decreased at the protein level in DKO mice compared to ApoE KO mice. Therefore, the reduced levels of these nuclear receptors involved in transcriptional regulation of lipid transport and uptake receptors leads to the reduced expression of the latter, which in turn would account for reduced liver uptake of lipids and hence reduced hepatic steatosis. This is supported by a study which demonstrated that liver specific disruption of PPAR-␥ attenuated hepatic steatosis. 31 Consequently, the significant reduction of lipoprotein uptake by the liver resulted in significant increases in plasma cholesterol and triglycerides, which in turn likely caused increased atherosclerotic burden in DKO mice.
Previously published reports have shown that UII induces ACAT expression in macrophages. 13 In addition, we have previously shown a reduction in ACAT expression with UII blockade using SB-657510, a potent UII antagonist in vivo. 32 Therefore, we were interested in identifying whether there was any effect on ACAT expression and activity in our UT deletion mouse model. Interestingly, we found that there was a significant reduction in ACAT protein expression in DKO mice compared to ApoE KO mice. Next, we examined whether UII also mediates alterations in ACAT activity.
Indeed, UII significantly induced cholesterol esterification in primary mouse hepatocytes, and this effect was completely abolished with the addition of PD98059, a MEK inhibitor. Therefore, this supports the notion that UII signaling blockade by UT gene deletion attenuates ACAT activity, thus reducing cholesterol esterification and storage in the liver. Indeed, others have shown decreased hepatic cholesterol with low ACAT activity. [33] [34] [35] [36] In addition, Sahlin et al previously demonstrated increased hepatic steatosis was associated with increased ACAT activity. 37 Furthermore, inhibition of UII-induced ACAT activity with a MEK inhibitor is in complete agreement with a previous study by Watanabe et al, who demonstrated MEKsensitive UII-induced ACAT expression in macrophages. 13 Here we provide strong evidence for the mechanism of hyperlipidemia in DKO mice. When we include this latter data with the fact that DKO mice are hyperinsulinemic and that UT gene deletion leads to a hypertensive phenotype with significantly elevated pulse pressure, there is a clear stimulus for the increased atherosclerosis found in these mice. Indeed hypertension, hyperinsulinemia, and hyperlipidemia are all major risk factors for endothelial dysfunction and atherosclerosis. 16, 38 Furthermore, increased systolic pressure and the severity of atherosclerosis may account for the increased heart weight seen in DKO mice.
To summarize, we show that UT gene deletion leads to increased blood pressure and hypertriglyceridemia, as well as decreased body weight gain, hepatic steatosis, and liver size in mice with a WT genetic background fed a high-fat diet. While UT deletion in an ApoE KO genetic background leads to significantly increased atherosclerotic lesion formation, serum lipids, as well as a significant decrease in body weight gain, liver mass, and hepatic steatosis. Here we show that the DKO phenotype of increased serum lipids and decreased hepatic lipid content is the result, at least in large part, of decreased lipoprotein uptake or decreased cholesterol esterification and storage resulting from attenuated ACAT expression and activity in our UT deletion mouse model. The combination of increased serum lipids, hyperinsulinemia, and hypertension in these mice clearly supports the increased atherosclerosis found in these mice. Graph demonstrating the percent of cholesterol esters to total cholesterol as determined in WT mouse primary hepatocytes. UII significantly induced cholesterol esterification, and this was significantly inhibited by PD98059, a MEK inhibitor. ACATi (ACAT inhibitor), PD (PD98059, MEK inhibitor), SB (SB203580, p38 kinase inhibitor).
